Compare Bristol-Myers Squibb Co (BMY) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Dicks Sporting Goods Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while Dicks Sporting Goods Inc trades at $202.67 (market cap $18.35B). The key difference: Bristol-Myers Squibb Co is far larger — about 7.1× Dicks Sporting Goods Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | DKS | |
|---|---|---|
Market Cap | $129.94B | $18.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $239.17 |
52-Week Low | $42.60 | $187.78 |
Enterprise Value | $163.92B | $25.14B |
Dividend Yield | 3.96% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Dick's Sporting Goods (DKS) trades at $202.66, down 5.34% on the day, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a 4.71% net income margin and 20.9% ROE, while analyst consensus remains strongly bullish with a $263.22 price target. Recent news highlights DKS as a value stock pick with accelerating sales growth, though the stock faces near-term technical pressure.
The outlook remains positive given strong analyst support and consistent earnings performance, but investors should monitor the bearish technical indicators and upcoming Q2 2026 earnings report on August 25th. Key risks include retail sector competition and potential margin pressure as revenue growth outpaces profit growth in 2026 projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
